Approved indications: Elrexfio is approved in the U.S. for adult patients with relapsed or refractory multiple myeloma whose disease has come back or not responded after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody; approval is accelerated and based on response rates and durability of response.

Off-label uses: Use outside this late-line multiple myeloma setting (for example earlier in the disease course or in combination regimens) is investigational, generally limited to clinical trials, and not considered standard off-label practice in routine care.

Efficacy expectations: In the pivotal MagnetisMM-3 study of heavily pretreated adults, about 6 in 10 patients achieved a partial response or better, with many deep responses (complete responses in roughly one-third of patients) and a median time to response of about 1 to 2 months; responses have been durable, with most responders still in remission at 1 to 2 years of follow-up and the median duration of response not yet reached as of recent analyses. Compared with other BCMA-targeted bispecific antibodies, overall response rates and depth of response are broadly similar, while Elrexfio’s ability to move from weekly to every-2-week and then every-4-week dosing in stable responders can reduce visit burden relative to agents that must be given more frequently or to one-time CAR-T therapies that require complex manufacturing but may offer higher response rates.

How Elrexfio is given: Elrexfio is administered only by a healthcare professional as a subcutaneous injection, usually into the abdomen or thigh, using a step-up schedule (12 mg on day 1, 32 mg on day 4, then 76 mg on day 8) followed by 76 mg weekly through week 24, then every 2 weeks from week 25 and potentially every 4 weeks from week 49 onward in responders, continued until disease progression or unacceptable toxicity.

Pretreatment and visit logistics: Before each of the two step-up doses and the first full 76 mg dose, patients receive premedications (such as acetaminophen, an antihistamine, and a corticosteroid) to reduce the risk of CRS, and they are typically observed in the hospital for 48 hours after the first step-up dose and 24 hours after the second; later doses are usually given in the outpatient clinic with shorter observation.

Special dosing instructions: The dosing interval may be delayed or restarted at lower step-up doses if certain side effects (for example significant CRS, neurologic toxicity, or severe neutropenia or infection) occur; dose reductions are generally not used, but temporary holds and careful re-escalation are common. Patients may also be prescribed infection prophylaxis (such as antivirals or antibiotics) and growth factors or transfusions to manage low blood counts.

What patients should do for missed doses: If a treatment visit is missed or delayed, patients should not attempt self-injection; they should contact their oncology team promptly so the schedule can be safely adjusted, as the prescriber may need to repeat part of the step-up regimen depending on how long it has been.

Overdose or extra dosing: In case of accidental extra dosing or concern for overdose, urgent medical evaluation is needed so clinicians can monitor for and treat complications like CRS, neurologic symptoms, or severe blood count changes with supportive care in a hospital setting.

Common side effects (usually mild to moderate):

• Cytokine release syndrome (CRS) with fever, chills, low blood pressure, or trouble breathing, most often during the first week step-up doses and first full dose.
• Fatigue, injection-site reactions, diarrhea, nausea, decreased appetite, rash, cough, and fever.
• Infections such as upper respiratory infections and pneumonia, and blood count changes (low white cells, red cells, or platelets) that can cause infection risk, anemia, or easy bruising.

Many patients experience at least one of these effects, especially early in treatment; most are manageable with monitoring, supportive medicines, and temporary treatment holds if needed.

Serious or less common adverse effects needing urgent attention:

• Severe CRS with high fever, confusion, chest pain, very low blood pressure, or severe breathing difficulty.
• Neurologic toxicity, including ICANS, with confusion, difficulty speaking, drowsiness, seizures, or sudden changes in behavior or coordination.
• Serious infections (pneumonia, sepsis, COVID-19, urinary infections) or febrile neutropenia.
• Significant liver test elevation or other organ problems.

Patients are usually watched in the hospital for 48 hours after the first step-up dose and 24 hours after the second step-up dose so these reactions can be treated quickly.

Warnings and precautions:

• Pregnancy: Elrexfio may harm an unborn baby; pregnancy should be avoided, and effective contraception is recommended during treatment and for several months (at least 4 months per U.S. labeling) after the last dose.
• Breastfeeding: Breastfeeding is not recommended during therapy and for several months after the last dose, because it is unknown if the drug passes into breast milk.
• Age limits: Safety and effectiveness have been established only in adults; it is not approved for children.
• Kidney or liver disease: No routine dose adjustment is specified, but patients with significant renal or hepatic impairment need close monitoring because they may be more vulnerable to infections, CRS, and lab abnormalities.

Safety compared with similar drugs: Elrexfio has a safety profile similar to other BCMA-directed bispecific antibodies, with high rates of CRS, infections, and cytopenias but mostly low-grade CRS when given with the step-up schedule; CAR-T therapies share many of these risks but differ in timing and logistics.

Side-effect reporting and safety updates: Side effects should be reported promptly to the treating oncology team; in the U.S., patients and clinicians can also report suspected adverse reactions to FDA MedWatch or to Pfizer, and updated safety communications are posted on the FDA and manufacturer websites as more data become available.

Drug and supplement interactions:

• Elrexfio can cause cytokine release that temporarily suppresses liver CYP enzymes, which may increase blood levels of other medicines that depend on these enzymes (for example, some blood thinners, seizure medications, opioids, and other drugs with a narrow therapeutic index); close monitoring and dose adjustments of these concomitant drugs may be needed especially during the first step-up doses and any episodes of CRS.
• No specific food interactions are known, and the drug is not taken by mouth, but alcohol should be used cautiously because it can worsen liver stress, dizziness, and infection risk.
• Live vaccines are generally avoided shortly before and during therapy and for a period afterward because of immune suppression; inactivated vaccines may be given but may work less well, so timing should be coordinated with the oncology team.

Conditions and co-medications that require extra caution:

• Active or recurrent infections (including chronic viral infections) increase the risk of serious infectious complications and usually must be treated and stabilized before starting Elrexfio.
• Pre-existing neurologic disorders (prior seizures, stroke, or significant cognitive impairment) may increase the impact of neurologic toxicity; such patients need careful risk–benefit discussion and close monitoring.
• Significant kidney or liver dysfunction, uncontrolled heart or lung disease, or poor performance status can make CRS or infections more dangerous and warrant individualized assessment.
• Concurrent use of other strong immunosuppressive drugs (for example, high-dose steroids or other biologic agents) can further raise infection risk and should be reviewed carefully.

Monitoring needs:

• Frequent vital signs and clinical assessments, especially around early doses, to detect CRS and neurologic toxicity promptly.
• Regular blood tests, including complete blood counts and liver and kidney function, to track cytopenias and organ effects.
• Ongoing evaluation for signs and symptoms of infection, with a low threshold for cultures and imaging when indicated.
• Assessment of neurologic status (orientation, speech, handwriting, balance) during treatment, especially in the first weeks and after dose changes.

Q: What does Elrexfio treat and who is it for?
A: Elrexfio is used for adults with multiple myeloma whose disease has come back or stopped responding after at least four prior treatments that included a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

Q: How quickly might I notice that Elrexfio is working?
A: In clinical trials, many patients who responded did so within about 1 to 2 months of starting therapy, though some responses took longer and scans and blood tests are needed to judge benefit.

Q: How long will I need to stay on Elrexfio?
A: Treatment is continued as long as it is controlling the myeloma and side effects remain manageable, with dosing usually weekly at first and then every 2 weeks and possibly every 4 weeks once a stable response is achieved.

Q: What are the most important side effects I should watch for at home?
A: You should call your care team or seek emergency help right away for high fever, breathing trouble, chest pain, confusion, severe weakness, or signs of infection such as shaking chills, new cough, or burning with urination, as these can signal CRS, neurologic toxicity, or serious infection.

Q: Can I get vaccines while being treated with Elrexfio?
A: Live vaccines are generally avoided shortly before, during, and for some time after treatment, but many inactivated vaccines can still be given; your oncology team will advise on which vaccines are appropriate and when to receive them.

Q: Will I be able to drive or work after my injections?
A: Because CRS and neurologic symptoms are most likely around the early doses, you will often be observed in the hospital after those injections and may be advised not to drive or do hazardous tasks until you and your team are confident you are not experiencing dizziness, confusion, or other side effects.